Drug intelligence / Profile preview

Eurasian H5 subtype avian influenza vaccine

Development stage: Preclinical
Lead developer: Harris Vaccines
Modality: mRNA Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
Administration: Subcutaneous, Intratracheal, Ophthalmic, In Ovo, Sublingual, Intranasal, Intramuscular, Oral, Inhalation

Overview

This vaccine, developed by Harrisvaccines, Inc. and later acquired by Merck Animal Health, is designed to combat the Eurasian H5 subtype of avian influenza. It utilizes proprietary RNA Particle (RP) technology, which allows for rapid development of herd-specific vaccines for emerging diseases. The acquisition by Merck aimed to accelerate its development and broaden its market access.

Targets

H5 HA (Influenza A hemagglutinin H5)

Beyond the preview

Go deeper on Eurasian H5 subtype avian influenza vaccine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Eurasian H5 subtype avian influenza vaccine.

Explore the full profile